Novacyt partners with Applied Microarrays

Published: 13-Sep-2018
Analysis

The US partnership aims to facilitate the design and optimisation of customised microarray assays


Novacyt, an international specialist in clinical diagnostics, has announced that its molecular testing division, Primerdesign, has partnered with Applied Microarrays (AMI), a company that specialises in providing customised microarrays, manufacturing point-of-care (POC), high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development.

Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome.

Alastair Malcolm, President and CEO of AMI, commented: “Through working with Primerdesign, we have been impressed with their assay development expertise and ability to deliver a high quality service in a timely manner. I am confident that our partnership will help us to deliver multiplexed probe based diagnostic and detection with better diagnosis and improved patient outcomes.”

Primerdesign has 13 years of experience in molecular assay design and this partnership highlights the division’s pivotal role in assay development as it grows its relationships with leading diagnostic companies.

Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings.

Graham Mullis, Group CEO of Novacyt, added: “I am delighted that we are entering into a partnership with AMI. This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business."

“I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships. We are increasingly becoming the partner of choice for molecular diagnostic companies and I look forward to updating shareholders with further partnerships like this.”

Financial terms of the agreement have not been disclosed.

  • Companies:
  • The Novacyt Group
See more

You may also like

Manufacturing

Novacyt partners with Genepoc to diagnose respiratory infections

Read more
An international specialist in clinical diagnostics has entered into a clinical assay development contract with a Canadian company, which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases

Trending Articles

  1. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis
  2. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  3. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Meeting new USP Chapter 41 requirements Balances are the essential means by which all therapeutics are ultimately supplied in safe dosages. Dirk Ahlbrecht, Sartorius Group, looks at how to ensure measurements are both accurate and up to new USP standards
  5. How microfluidic diffusional sizing can enhance your protein assays MDS can enhance the information gained from an assay experiment and allow the timely and guided production of novel protein and antibody-based therapeutics

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

Novacyt partners with Genepoc to diagnose respiratory infections

An international specialist in clinical diagnostics has entered into a clinical assay development contract with a Canadian company, which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases
Analysis

Novacyt announces further progress in China

Novacyt, an international specialist in clinical diagnostics, has received its largest single order for Primerdesign’s genesig q16 instruments
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Sustainability

Efficient PFAS-free degassing of aqueous solutions

New silicone-based degassing chamber eliminates the risk of PFAS contamination
Research & Development

Medac and chiron develop organ-on chip tech for animal free drug testing

The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
Research & Development

INTEGRA Bioscience's pipettes for streamlined and accurate liquid handling

Bioanalytical consultancy company BioApp solutions is currently using INTEGRA's pipettes to improve its pipetting consistency, and — therefore — the reproducibility of its results
Analysis

SGS expands cutting-edge spray drug delivery testing capabilities in Belgium health science laboratory

SGS, the world’s leading testing, inspection and certification company, has announced an expansion in its spray drug delivery testing capabilities at their laboratory in Wavre, Belgium
Subscribe now